Trial · NCT04445987
Results by group74
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 74
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With ≥1 Adverse Event (AE) | Cohort 1 Group 1: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | 17 | Participants | ||
| Number of Participants With ≥1 Adverse Event (AE) | Cohort 2 Groups 3 and 4: ARQ-154-203 Roflumilast Foam 0.3% With Treatment Gap | 23 | Participants | ||
| Number of Participants With ≥1 Adverse Event (AE) | Cohort 2 Group 4: De Novo Participants | 90 | Participants | ||
| Number of Participants With ≥1 Adverse Event (AE) | Cohort 1 Group 2: ARQ-154-116 Rollover | 3 | Participants | ||
| Number of Participants With ≥1 Serious Adverse Event (SAE) | Cohort 1 Group 1: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | 2 | Participants | ||
| Number of Participants With ≥1 Serious Adverse Event (SAE) | Cohort 2 Group 3: ARQ-154-203 Roflumilast Foam 0.3% With Treatment Gap | 0 | Participants | ||
| Number of Participants With ≥1 Serious Adverse Event (SAE) | Cohort 2 Group 4: De Novo Participants | 5 | Participants | ||
| Number of Participants With ≥1 Serious Adverse Event (SAE) | Cohort 1 Group 2: ARQ-154-116 Rollover | 0 | Participants | ||
| Number of Participants With an Investigator Global Assessment (IGA) Score of Completely Clear or Almost Clear | Cohort 1 Group 1: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | Week 4 | 36 | Participants | |
| Number of Participants With an Investigator Global Assessment (IGA) Score of Completely Clear or Almost Clear | Cohort 1 Group 1: ARQ 154-203 Vehicle Foam Rolled Over Without Treatment Gap | Week 4 | 7 | Participants | |
| Number of Participants With an Investigator Global Assessment (IGA) Score of Completely Clear or Almost Clear | Cohort 2 Group 3: ARQ-154-203 Roflumilast Foam 0.3% With Treatment Gap | Week 4 | 20 | Participants | |
| Number of Participants With an Investigator Global Assessment (IGA) Score of Completely Clear or Almost Clear | Cohort 2 Group 3: ARQ-154-203 Vehicle Foam With Treatment Gap | Week 4 | 10 | Participants | |
| Number of Participants With an Investigator Global Assessment (IGA) Score of Completely Clear or Almost Clear | Cohort 2 Group 4: De Novo Participants | Week 4 | 137 | Participants | |
| Number of Participants With an Investigator Global Assessment (IGA) Score of Completely Clear or Almost Clear | Cohort 1 Group 2: ARQ-154-116 Rollover | Week 4 | 5 | Participants | |
| Number of Participants With an Investigator Global Assessment (IGA) Score of Completely Clear or Almost Clear | Cohort 1 Group 1: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | Week 12 | 35 | Participants | |
| Number of Participants With an Investigator Global Assessment (IGA) Score of Completely Clear or Almost Clear | Cohort 1 Group 1: ARQ 154-203 Vehicle Foam Rolled Over Without Treatment Gap | Week 12 | 7 | Participants | |
| Number of Participants With an Investigator Global Assessment (IGA) Score of Completely Clear or Almost Clear | Cohort 2 Group 3: ARQ-154-203 Roflumilast Foam 0.3% With Treatment Gap | Week 12 | 25 | Participants | |
| Number of Participants With an Investigator Global Assessment (IGA) Score of Completely Clear or Almost Clear | Cohort 2 Group 3: ARQ-154-203 Vehicle Foam With Treatment Gap | Week 12 | 12 | Participants | |
| Number of Participants With an Investigator Global Assessment (IGA) Score of Completely Clear or Almost Clear | Cohort 2 Group 4: De Novo Participants | Week 12 | 172 | Participants | |
| Number of Participants With an Investigator Global Assessment (IGA) Score of Completely Clear or Almost Clear | Cohort 1 Group 2: ARQ-154-116 Rollover | Week 12 | 5 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04445987/results